Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Key Laboratory of Bioinformatics and Molecular Imaging, Department of Biotechnology, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Key Laboratory of Bioinformatics and Molecular Imaging, Center for Artificial Intelligence Biology, Department of Bioinformatics and Systems Biology, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Gut Microbes. 2024 Jan-Dec;16(1):2420771. doi: 10.1080/19490976.2024.2420771. Epub 2024 Nov 3.
Probiotics hold great potential for treating metabolic diseases such as obesity. Given the complex and multifactorial nature of these diseases, research on probiotic combination with multiple targets has become popular. Here, we choose four obesity-related targets to perform high-throughput screening, including pancreatic lipase activity, bile salt hydrolase activity, glucagon-like peptide-1 secretion and adipocyte differentiation. Then, we obtained 649 multi-strain combinations with the requirement that each must cover all these targets in principle. After co-culture and co-colonization experiments, only four (<0.7%) combinations were selected as symbiotic probiotic communities (SPCs). Next, genome-scale metabolic model analysis revealed that these SPCs showed lower metabolic resource overlap and higher metabolic interaction potential involving amino acid metabolism (Ammonium, L-Lysine, etc.) and energy metabolism (Phosphate, etc.). Further animal experiments demonstrated that all SPCs exhibited a good safety profile and excellent effects in improving obesity and associated glucose metabolism disruptions and depression-like behaviors in high-fat-diet-fed mice. This anti-obesity improvement was achieved through reduced cholesterol level, fat accumulation and inhibited adipocyte differentiation. Taken together, our study provides a new perspective for designing multi-strain combinations, which may facilitate greater therapeutic effect on obesity and other complex diseases in the future.
益生菌在治疗肥胖等代谢性疾病方面具有巨大潜力。鉴于这些疾病的复杂性和多因素性质,研究益生菌与多个靶点的组合已成为热门话题。在这里,我们选择了四个与肥胖相关的靶点进行高通量筛选,包括胰脂肪酶活性、胆盐水解酶活性、胰高血糖素样肽-1 分泌和脂肪细胞分化。然后,我们获得了 649 种多菌株组合,原则上每个组合都必须涵盖所有这些靶点。经过共培养和共定植实验,只有四个(<0.7%)组合被选为共生益生菌群落(SPCs)。接下来,基因组规模的代谢模型分析表明,这些 SPCs 表现出较低的代谢资源重叠和更高的代谢相互作用潜力,涉及氨基酸代谢(铵、L-赖氨酸等)和能量代谢(磷酸盐等)。进一步的动物实验表明,所有 SPC 均表现出良好的安全性,并能显著改善高脂肪饮食喂养的小鼠的肥胖及其相关的葡萄糖代谢紊乱和抑郁样行为。这种抗肥胖的改善是通过降低胆固醇水平、脂肪积累和抑制脂肪细胞分化来实现的。总之,我们的研究为设计多菌株组合提供了一个新的视角,这可能有助于未来在肥胖症和其他复杂疾病方面取得更大的治疗效果。